Progenics Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown,
NY 10591
United States - Map
Phone: 914-789-2800
Fax: 914-789-2817
Website: http://www.progenics.com
Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States and internationally. Its primary programs focus on gastroenterology, oncology, and virology. The company offers RELISTOR (methylnaltrexone bromide) subcutaneous injection, a therapy for opioid-induced constipation. It is also conducting a Phase I clinical trial of a human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells, as well as in blood vessels supplying other solid tumors. In addition, the company is developing PRO 140, a viral-entry inhibitor for human immunodeficiency virus (HIV), which is in Phase II clinical testing; and multiplex PI3-Kinase inhibitors for the treatment of cancer. Progenics Pharmaceuticals, Inc. has license agreement with Salix Pharmaceuticals, Ltd. for the development and commercialization of RELISTOR worldwide other than Japan. The company was founded in 1986 and is based in Tarrytown, New York. Key Statistics
| |
| Progenics Pharmaceuticals Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (High Concern), Compensation (Medium Concern), Shareholder Rights (Low Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Mark R. Baker J.D.,
57
Chief Exec. Officer, Director, Member of Science & Technology Committee and Member of Strategy & External Technology Subcommittee | 837.00K | 0.00 | Mr. Robert A. McKinney CPA,
55
Chief Financial Officer, Principal Accounting Officer, Sr. VP of Fin. & Operations and Treasurer | 476.00K | 0.00 | Dr. Robert J. Israel M.D.,
55
Sr. VP of Medical Affairs & Clinical Research | 554.00K | 22.00K | Mr. Benedict Osorio M.S., M.B.A,
55
Sr. VP of Quality | 444.00K | 0.00 | Dr. Stephen P. Goff Ph.D.,
60
Chairman of the Virology Scientific Advisory Board, Scientific Advisor, Independent Director, Chairman of Science & Technology Committee and Member of Nominating & Corp. Governance Committee | 66.00K | N/A |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq 
0.34(4.19%) May 25, 4:00PM EDT|After Hours:
8.45 0.00 (0.00%) May 25, 4:47PM EDT